Abstract
Background The differential diagnosis of α-synucleinopathies, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), is challenging due to overlapping clinical features and the current lack of reliable biomarkers. The primary diagnostic approach remains clinical, underscoring the need for objective biomarkers that can distinguish between these diseases. This study profiles α-synuclein peptides in plasma to explore potential disease-specific patterns.
Methods We developed a targeted mass spectrometry-based assay to profile α-synuclein in plasma samples from PD (n=82), DLB (n=32), MSA (n=8), and controls (n=21). The assay quantifies non-modified peptides specifically derived from the N-terminus and NAC domain, regions implicated in aggregate formation, to assess potential disease-specific peptide patterns.
Results No significant differences in peptide levels were observed between the disease groups, indicating consistent N-terminus and NAC domain profiles among α-synucleinopathies. However, a peptide within the NAC domain showed distinct patterns in MSA compared to other groups, which may reflect unique pathological processes.
Conclusions This study provides the first blood-based assessment of α-synuclein peptide profiles, establishing a basis for future research into α-synucleinopathies. Refining the assay to include post-translationally modified peptides may enhance understanding of disease mechanisms and improve biomarker development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors have no conflict of interest to report. Mass spectrometry experiments were carried out using the facilities of the Montpellier Proteomics Platform (PPM-PPC, BioCampus Montpellier). This article has been written in the context of the innovation center of Shimadzu Europa GmbH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the participants gave their written consent to be enrolled in the study which was approved by the Montpellier University Hospitals regional Ethics Committee. Authorization to handle personal data was granted by the French Data Protection Authority (CNIL).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email addresses of authors:
Marie-Laure Pons : marielaurepons43{at}gmail.com
Pablo Mohaupt : pablo.mohaupt{at}chu-montpellier.fr
Jérôme Vialaret : j-vialaret{at}chu-montpellier.fr
Etienne Mondesert : e-mondesert{at}chu-montpellier.fr
Margaux Vignon : margaux.vignon{at}umontpellier.fr
Salomé Coppens : salome.coppens{at}umontpellier.fr
Moreau Stéphane : sm{at}shimadzu.eu
Sylvain Lehmann : sylvain.lehmann{at}umontpellier.fr
Christophe Hirtz : christophe.hirtz{at}umontpellier.fr
We conducted a comprehensive and rigorous revision of the manuscript, resulting in significant changes to the findings. This involved reprocessing and reanalyzing the data, completely rewriting the text, and adding new figures, plots, and tables. While the revision builds on the initial analysis, it reflects a different set of results and insights.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
List of abbreviations
- AD
- Alzheimer’s disease
- AUC
- Area under the curve
- CMRR
- Montpellier Memory Resources Center
- CSF
- Cerebrospinal fluid
- DLB
- Dementia with Lewy bodies
- NAC
- Non-amyloid-β component
- NfL
- Neurofilament light chain
- MRM
- Multiple Reaction Monitoring
- MSA
- Multiple system atrophy
- MTBR
- Microtubule-binding region
- PD
- Parkinson’s disease
- PDD
- Parkinson’s disease with dementia
- pTau217
- Tau protein with phosphorylation at the 217th amino acid residue
- ROC
- Receiver operating characteristic
- SPE
- Solid-phase extraction